Eli Lilly stock slips after Novo Nordisk trims 2025 forecast; Jaypirca meets endpoint in CLL trial against J&J's Imbruvica, ...

* Researchers at the Danish Headache Center are testing semaglutide along with a very low calorie diet as a treatment for new ...

Tirzepatide use vs placebo was associated with slower decline in eGFR among patients with prediabetes and obesity or overweight.

The company has looked internally for its new leader, as Doustdar is currently serving as its head of international ...

The top-line outcomes from SUPREME-01 are anticipated between the fourth quarter of 2026 and the first quarter of 2027.

Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...

Comedian and Emmy-nominated actor Kym Whitley opens up about her long journey with weight management. The "Happy Gilmore 2" ...

There's been plenty of buzz about this class of drug, following publication of a high-profile trial this year. How much do we ...

Eli Lilly and Company (NYSE:LLY) is experiencing a strong analyst sentiment amid its expanding role in cutting-edge ...

The risks of the new weight-loss drugs can sound scary, and there’s lots of talk about side effects. What does evidence show?

The illicit supply of unregulated weight loss drugs is becoming an ‘emerging concern’ for Police Scotland and the.